International Journal of Radiation Oncology * Biology * Physics
Volume 76, Issue 1 , Pages 5-8 , January 2010

Lin28-let7 Modulates Radiosensitivity of Human Cancer Cells With Activation of K-Ras

  • Jee-Sun Oh, M.S.

      Affiliations

    • Medical Science Research Institute, Seoul National University Bundang Hospital, Seongnamsi, Korea
    • ,
  • Jae-Jin Kim, B.S.

      Affiliations

    • Medical Science Research Institute, Seoul National University Bundang Hospital, Seongnamsi, Korea
    • ,
  • Ju-Yeon Byun, M.S.

      Affiliations

    • Medical Science Research Institute, Seoul National University Bundang Hospital, Seongnamsi, Korea
    • ,
  • In-Ah Kim, M.D., Ph.D.

      Affiliations

    • Department of Radiation Oncology, Cancer Research Institute, Seoul National University, Seoul, Korea
    • Corresponding Author InformationReprint requests to: In-Ah Kim, Department of Radiation Oncology, Seoul National University Bundang Hospital, 300 Gumidong Seongnamsi, Kyeonggido, Korea, 463-707. Tel: (+82) 31-787-7651

Received 5 February 2009 ,Revised 24 June 2009 ,Accepted 10 August 2009.

References 

  1. Lai EC. MicroRNAs are complementary to 3′UTR motifs that mediate negative post-transcriptional regulation. Nat Genet. 2002;30:363–364
  2. Esquela-Kerscher A, Slack FJ. Oncomir-microRNAs with a role in cancer. Nat Rev. 2006;6:259–269
  3. Johnson SM, Grosshans H, Jaclyn S, et al. RAS is regulated by the let7 microRNA family. Cell. 2005;120:635–647
  4. Morris IVJP, McManus MT. Slowing down Ras lane: miRNAs as tumor suppressors?. Science SKTE. 2005;297/pe41:1–4
  5. Downward J. Targeting RAS signaling pathways in cancer therapy. Nat Rev Cancer. 2003;3:11–22
  6. Kim IA, Bae SS, Fernandes A, et al. Selective inhibition of Ras, phosphoinositide 3 kinase and Akt isoforms increases the radiosensitivity of human carcinoma cell lines. Cancer Res. 2005;65:7902–7910
  7. Heo I, Joo C, Cho J, et al. Lin28 mediates the terminal uridylation of let-7 precursor microRNA. Mol Cell. 2008;32:276–284
  8. Kim IA, Shin JH, Kim IH, et al. Histone deacetylase inhibitor-mediated radiosensitization of human cancer cells: Class differences and the potential influence of p53. Clin Cancer Res. 2006;12:940–949
  9. Broermann P, Junker K, Brandt BH, et al. Trimodality treatment in stage III non-small cell lung carcinoma: Prognostic impact of K-ras mutations after neoadjuvant therapy. Cancer. 2002;94:2055–2062
  10. Dergham ST, Dugan MC, Kucway R, et al. Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma. Int J Pancreatol. 1997;21:127–143
  11. Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004;64:3753–3375
  12. Weidhaas JB, Babar I, Nallur S, et al. MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res. 2007;67:11111–11116

 J.-S. Oh, J.-J. Kim, and J.-Y. B. contributed equally to this study.

 Supported by grants from the Korean Ministry of Education, Science & Technology (BAERI #M20708630001-07B0863-00110 & KRF#E00381).

 Conflict of interest: none.

PII: S0360-3016(09)02969-1

doi: 10.1016/j.ijrobp.2009.08.028

International Journal of Radiation Oncology * Biology * Physics
Volume 76, Issue 1 , Pages 5-8 , January 2010

Article Tools

* Image Usage & Resolution